파이브로바이올로직스FBLG 주가

FibroBiologics Announces Preclinical Data From Its CYPS317 Program For Psoriasis Was Presented At The Society For Investigative Dermatology Meeting, May 13-15

Psoriasis is a chronic inflammatory skin disease driven by dysregulated innate and adaptive immunity, with the IL-23/Th17 axis playing a central role in sustaining disease activity. In an imiquimod-induced psoriasis

♻️ 재탕Fibrobiologics Inc - files provisional patent application for oral fibroblast therapeutics

FibroBiologics Inc: FibroBiologics Inc - files provisional patent application for oral fibroblast therapeutics...

FibroBiologics Files New Provisional Patent Application With USPTO Titled 'Oral Fibroblasts And Fibroblast-Derived Therapeutics And Delivery Systems For Same'

The application covers oral delivery systems designed to protect fibroblast-based therapeutics through the stomach and enable targeted release in the gastrointestinal tract.The provisional patent application describes an

FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics

HOUSTON, May 18, 2026 -- FibroBiologics, Inc. , a clinical-stage biotechnology company with 270+ patents issued and pending focused on the development of therapeutics and potential cures for...

Fibrobiologics Inc Expands Fibroblast Platform to Target Hantavirus

FibroBiologics, Inc. announced a strategic expansion of its fibroblast-based platform to target Hantavirus. Building on existing preclinical work in treating acute respiratory distress syndrome , the...

FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus

Will Apply Existing Preclinical Findings in Reducing Severe Immune-Mediated Lung Failure to Potential Emerging Global CrisisHOUSTON, May 11, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced a strategic expansion of its fibroblast-based plat

FibroBiologics Announces Strategic Expansion Of Its Fibroblast-Based Platform To Target Hantavirus

FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending focused on the development of therapeutics and potential cures for chronic diseases using

[8-K] 중대 사건 — 8-K

[424B5] 증자 가격 공시 — 424B5

FibroBiologics CEO Issues Letter to Shareholders

HOUSTON, May 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today issued the following letter to shareholders. Dear Fellow Shareholders, This year, FibroBiologics achieved a milestone we have been working toward over the past few years. We initi